Leading RTSM Innovation: Atreo 2.3 Release Highlights

The latest evolution in RTSM technology has arrived with the Atreo v2.3 "Dogwood" release, designed to bring unprecedented agility to clinical trials.

Atreo is driven by a passion to empower the life sciences industry to use time to its maximum potential. Our mission is to build scalable and trusted solutions that redefine predictability and quality, ensuring study teams spend less time on manual processes and more on patient progress.

Advanced Features of Our New RTSM Technology

The v2.3 Dogwood release exemplifies our vision to lead the next generation of RTSM technology. By focusing on user-centric design and technical robustness, we have introduced several key highlights:

• Role-Specific Dashboards: Provides teams with instant visibility into key study metrics like enrollment and patient visits.
• Site Audit Logs: Enhances transparency with on-demand audit trails for sponsor-controlled report availability.
• Single Sign-On (SSO): Allows users to access the platform using existing organizational credentials for a simplified experience.
• Enhanced Dose Management: Offers advanced control for sponsor users in the front-end, reducing the need for mid-study system changes.
• Satellite Functionality: Robust support for satellite sites to connect to parent sites and supply drugs directly.

Continuous Innovation in Clinical Supplies

Atreo commits to multiple core product releases annually to ensure your teams always benefit from a modern, simplified experience. Our RTSM technology is built to adapt to the fast-paced nature of modern clinical research, providing a "visual design" experience that removes the guesswork from study builds.

Ready to see the future of trial management? View our full product roadmap and discover how Atreo is redefining clinical supply chains.